Related references
Note: Only part of the references are listed.Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp)
Hang Zhang et al.
MEDICINAL RESEARCH REVIEWS (2021)
The Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Drug Transport Across Caco-2 Cell Monolayers
Iichiro Kawahara et al.
DRUG METABOLISM AND DISPOSITION (2020)
Assessment of contribution of BCRP to intestinal absorption of various drugs using portal-systemic blood concentration difference model in mice
Iichiro Kawahara et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Mechanism of allosteric modulation of P-glycoprotein by transport substrates and inhibitors
Reza Dastvan et al.
SCIENCE (2019)
Predicting Paclitaxel Disposition in Humans With Whole-Body Physiologically-Based Pharmacokinetic Modeling
Qiang Fu et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Intestinal P-glycoprotein inhibitors, benzoxanthone analogues
Song Wha Chae et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2018)
Effects of Catechins and Their Related Compounds on Cellular Accumulation and Efflux Transport of Mitoxantrone in Caco-2 Cell Monolayers
Narumi Sugihara et al.
JOURNAL OF FOOD SCIENCE (2017)
Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles
Prachi B. Shekhawat et al.
ACTA PHARMACEUTICA SINICA B (2017)
Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination
Christopher R. Jones et al.
AAPS JOURNAL (2016)
Structure-activity relationships of dibenzoylhydrazines for the inhibition of P-glycoprotein-mediated quinidine transport
Ken-ichi Miyata et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Design, synthesis and biological evaluation of LBM-A5 derivatives as potent P-glycoprotein-mediated multidrug resistance inhibitors
Yuxiang Wu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel
Kyeong Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
Seng Chuan Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel
Jeroen J. M. A. Hendrikx et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
In Vivo Assessment of the Impact of Efflux Transporter on Oral Drug Absorption Using Portal Vein-Cannulated Rats
Yoshiki Matsuda et al.
DRUG METABOLISM AND DISPOSITION (2013)
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
Joerg Koenig et al.
PHARMACOLOGICAL REVIEWS (2013)
In Situ Intestinal Perfusion in Knockout Mice Demonstrates Inhibition of Intestinal P-Glycoprotein by Ritonavir Causing Increased Darunavir Absorption
Nico Holmstock et al.
DRUG METABOLISM AND DISPOSITION (2010)
Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells
E. Roger et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone
Hiroshi Kodaira et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
The Effect of Wellsolve, a Novel Solubilizing Agent, on the Intestinal Barrier Function and Intestinal Absorption of Griseofulvin in Rats
Khuriah Abdul Hamid et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2009)
Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
Jurjen S. Lagas et al.
CLINICAL CANCER RESEARCH (2009)
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib
Roos L. Oostendorp et al.
INVESTIGATIONAL NEW DRUGS (2009)
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2)
Anne Pick et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Variability in Caco-2 and MDCK cell-based intestinal permeability assays
Donna A. Volpe
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
P-glycoprotein and breast cancer resistance protein: Two dominant transporters working together in limiting the brain penetration of topotecan
Nienke A. de Vries et al.
CLINICAL CANCER RESEARCH (2007)
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer
Szabolcs Modok et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques
Veronika Jekerle et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice
SZ Zhang et al.
DRUG METABOLISM AND DISPOSITION (2005)
The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics
Y Sambuy et al.
CELL BIOLOGY AND TOXICOLOGY (2005)
VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein
H Minderman et al.
CLINICAL CANCER RESEARCH (2004)
Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: Role of P-glycoprotein as a barrier to in vivo ocular drug absorption
S Dey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice
HA Bardelmeijer et al.
INVESTIGATIONAL NEW DRUGS (2004)
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement
MVS Varma et al.
PHARMACOLOGICAL RESEARCH (2003)
Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers
MD Troutman et al.
PHARMACEUTICAL RESEARCH (2003)
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)
S Callies et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Drug-drug interaction mediated by inhibition and induction of P-glycoprotein
JH Lin
ADVANCED DRUG DELIVERY REVIEWS (2003)
Modulation of P-glycoprotein but not MRPI- or BCRP-mediated drug resistance by LY335979
RL Shepard et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Drug interaction studies between paclitaxel (Taxol) and OC144-093 - A new modulator of MDR in cancer chemotherapy
ES Guns et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2002)
The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats
M Sababi et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2001)
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation
CJ Matheny et al.
PHARMACOTHERAPY (2001)
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
JW Jonker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
